相关临床试验
23
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1846
进行中（未招募）
1
4.3%
已完成
6
26.1%
尚未招募
9
39.1%
招募中
5
21.7%
终止
1
4.3%
Unknown
1
4.3%
暂无批准数据
- The ESPRESSo trial found that high-intensity therapy starting within two weeks of stroke did not improve hand and arm recovery beyond standard care, challenging the "more therapy, earlier" approach. - Sixty-four stroke survivors received an extra 90 minutes of daily therapy for three weeks, but showed identical three-month outcomes to patients receiving standard care alone. - The study suggests early stroke recovery is dominated by natural biological repair processes that cannot be enhanced by increasing therapy dose above standard care. - Results indicate that intensive therapy may be more effective later in recovery when patients can engage more fully, rather than during the acute phase.
- New Zealand-based Kitea Health has secured placement in the FDA fast-track program, accelerating the regulatory pathway for their innovative medical sensor technology. - The company recently achieved a world-first by successfully implanting their neural sensor into a child's brain, marking a significant milestone in pediatric neurosurgical interventions. - Kitea Health has raised $7 million toward a $10 million funding round, building on a decade of research before commercialization of their technology.
- University of Auckland and Auckland City Hospital researchers initiate a clinical trial to study severe cardiac side effects of 5-fluorouracil (5FU), a widely-used chemotherapy drug affecting 5% of patients. - The two-year study, funded by multiple organizations including the Gut Cancer Foundation, aims to identify risk factors and mechanisms behind 5FU-induced cardiotoxicity through comprehensive patient monitoring. - Researchers will utilize Holter monitors, blood tests, and urine samples from cancer patients to understand drug metabolism patterns and develop predictive markers for adverse cardiac reactions.
